{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/cellulitis-acute/prescribing-information/metronidazole/","result":{"pageContext":{"chapter":{"id":"0c0b7a3f-11e4-5b00-bd21-b66e49f9ad77","slug":"metronidazole","fullItemName":"Metronidazole","depth":2,"htmlHeader":"<!-- begin field df2d06e6-9d5c-4dbd-b6b2-aadb00bfb596 --><h2>Metronidazole</h2><!-- end field df2d06e6-9d5c-4dbd-b6b2-aadb00bfb596 -->","summary":"","htmlStringContent":"<!-- begin item 04a6cdaa-5997-43ff-a237-aadb00bfb52b --><!-- end item 04a6cdaa-5997-43ff-a237-aadb00bfb52b -->","topic":{"id":"c0841d82-0a64-5b27-81dc-9a825d85f1bf","topicId":"6db61277-29ef-49cc-bad1-d0d78d0afc10","topicName":"Cellulitis - acute","slug":"cellulitis-acute","lastRevised":"Last revised in January 2021","chapters":[{"id":"84376fdb-da2b-561d-bb40-28b5b1a7e975","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"bdf35905-533d-5cb1-bd18-9c1575427a25","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"d6c8c4bd-9395-5840-83c7-67ddfeabdf85","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"59d003f6-dd50-5136-b5c2-c2ea4e4b6f01","slug":"changes","fullItemName":"Changes"},{"id":"f79ca51e-9432-56b1-95de-92ed6133be2b","slug":"update","fullItemName":"Update"}]},{"id":"05002b30-8200-5ccf-b9da-7c96acdb65bd","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"fefb70b6-1d32-5e70-afc6-291fa40b3137","slug":"goals","fullItemName":"Goals"},{"id":"cf84220a-f381-5ca1-aa76-ffb99c4959f6","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"aa32cbb7-29d6-58b6-bcde-7702767672ec","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"7e039433-2afe-5980-93f0-c20c41976610","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"d1411fdd-dc83-5f20-9fa4-ad67b69c195a","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"ce40a600-51e8-5b3a-86c2-d127f03c16eb","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"ff60c523-3d6f-5766-8508-98e8cdcf08f5","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"8e8cfe4a-13f2-573c-ab45-7231016746c4","slug":"definition","fullItemName":"Definition"},{"id":"2b7befe3-0fef-5d4e-b00d-bad6742fb93c","slug":"causes","fullItemName":"Causes"},{"id":"96971948-f52b-561c-84f8-8600f3eff2d4","slug":"prevalence","fullItemName":"Prevalence"},{"id":"4749dc8a-3f24-5e65-a0a3-5d7665ef3085","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"ad3d41f6-595b-505c-b020-918f0e086d3f","slug":"complications","fullItemName":"Complications"},{"id":"82ccb916-06d4-5b29-91e4-90005f3db942","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"7305e6df-9b2c-5584-9412-54564432e382","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"8625eea6-53ec-5348-befa-a609ea64590f","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"273b1216-536e-59b4-8c39-547a97824ffa","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"68b86e3a-ee13-5ccd-9df0-a5c70c553251","fullItemName":"Management","slug":"management","subChapters":[{"id":"195394ca-067a-5cf3-bc4d-52a189d2cba6","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"4426193a-52c1-59b9-9222-77fb7169a3d1","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"78de19b8-8e80-551f-8112-456ce2e25bb0","slug":"amoxicillin","fullItemName":"Amoxicillin"},{"id":"73060223-dd90-59da-bae3-c706b5d24298","slug":"clarithromycin","fullItemName":"Clarithromycin"},{"id":"83f47301-e112-5f78-a79a-5c03a9de9537","slug":"co-amoxiclav","fullItemName":"Co-amoxiclav"},{"id":"b7240858-fbcc-5f20-8dcd-19f0b7221ac4","slug":"doxycycline","fullItemName":"Doxycycline"},{"id":"07828388-33ed-5e04-90b7-28a76fa26c6e","slug":"erythromycin","fullItemName":"Erythromycin"},{"id":"4600d0c1-4cd1-51ee-87a0-b660f0fa2165","slug":"flucloxacillin","fullItemName":"Flucloxacillin"},{"id":"0c0b7a3f-11e4-5b00-bd21-b66e49f9ad77","slug":"metronidazole","fullItemName":"Metronidazole"},{"id":"29987f8b-20b6-5c1f-8d23-183b415a04fb","slug":"analgesia","fullItemName":"Analgesia"}]},{"id":"4b09dc1a-8268-50d6-a164-227a73b3556e","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"d49b86e1-77b2-58e6-82c0-ea0aa7ee74ed","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"fe910063-69df-5218-bb78-36f5863db2a1","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"129f5233-2934-55ad-a561-4eb37861dc10","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"74d5b6b4-ef9d-5fc4-b41b-656b81a7ded8","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"44402335-ffeb-5e14-9e77-bb8278ef43d6","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"04d7d640-f586-53d9-ac59-804c10dd593d","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"c50af1ff-f157-5023-92b4-aa07b1c28d76","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"4426193a-52c1-59b9-9222-77fb7169a3d1","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"e64e8f93-2dd3-5572-a028-40f19d0d0af8","slug":"contraindications-cautions","fullItemName":"Contraindications and cautions","depth":3,"htmlHeader":"<!-- begin field 91f6fa20-a9bf-4afe-bdce-aadb00c0b715 --><h3>What are the contraindications and cautions for metronidazole?</h3><!-- end field 91f6fa20-a9bf-4afe-bdce-aadb00c0b715 -->","summary":"","htmlStringContent":"<!-- begin item fe059232-2513-4fc5-a0fa-aadb00c0b6ec --><!-- begin field 43ce898b-0155-47a4-8902-aadb00c0b715 --><ul><li><strong>Do not prescribe metronidazole in people with:</strong><ul><li>Known metronidazole or nitroimidazole hypersensitivity.</li></ul></li><li><strong>Prescribe metronidazole with caution in people with:</strong><ul><li>Cockayne syndrome — cases of severe hepatotoxicity/acute hepatic failure, including cases with a fatal outcome with very rapid onset after treatment initiation in patients with Cockayne syndrome have been reported with products containing metronidazole for systemic use (oral and suppositories).</li><li>Only prescribe after careful benefit-risk assessment and only if no alternative treatment is available. Liver function tests must be performed just prior to the start of therapy, throughout and at the end of treatment until liver function is within normal ranges, or until the baseline values are reached.</li><li>Active or chronic severe peripheral and central nervous system disease, as there is a risk of neurological aggravation.</li><li>Severe liver disease or hepatic encephalopathy — prescribe one-third of the daily dosage once daily.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/cellulitis-acute/references/\">ABPI, 2017c</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/cellulitis-acute/references/\">Joint Formulary Committee, 2019</a>] </p><!-- end field 43ce898b-0155-47a4-8902-aadb00c0b715 --><!-- end item fe059232-2513-4fc5-a0fa-aadb00c0b6ec -->","subChapters":[]},{"id":"e794e57b-3f9d-5b8e-bab3-6b2e72a65726","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field d8dd5ec0-81eb-4852-abda-aadb00c0c67a --><h3>What are the possible adverse effects of metronidazole?</h3><!-- end field d8dd5ec0-81eb-4852-abda-aadb00c0c67a -->","summary":"","htmlStringContent":"<!-- begin item 97873875-1bc4-4164-a2d6-aadb00c0c657 --><!-- begin field 9e0a5cff-864c-4168-b92a-aadb00c0c67a --><ul><li><strong>Blood disorders </strong>— agranulocytosis, neutropenia, thrombocytopenia, pancytopenia (very rare).</li><li><strong>Eye </strong>— transient diploplia, or myopia (very rare).</li><li><strong>Gastrointestina</strong>l — nausea, vomiting, anorexia, epigastric pain, taste disturbances, furred tongue, oral mucositis (unknown frequency).</li><li><strong>Nervous system</strong> — drowsiness, dizziness, convulsions, headaches, encephalopathy (very rare)</li><li><strong>Psychiatric</strong> — confusion, hallucinations (very rare).</li><li><strong>Skin —</strong> rash, pruritus, flushing, erythema multiforme, Stevens-Johnson syndrome or toxic epidermal necrolysis, fixed drug eruption (very rare).</li><li><strong>Other rare, or very rare adverse effects include</strong>:<ul><li>Anaphylaxis.</li><li>Darkening of urine.</li><li>Hearing impairment, tinnitus.</li><li>Liver enzyme increases, jaundice, pancreatitis.</li><li>Myalgia, arthralgia.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/cellulitis-acute/references/\">ABPI, 2017c</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/cellulitis-acute/references/\">Joint Formulary Committee, 2019</a>]</p><!-- end field 9e0a5cff-864c-4168-b92a-aadb00c0c67a --><!-- end item 97873875-1bc4-4164-a2d6-aadb00c0c657 -->","subChapters":[]},{"id":"1b9813ca-bef4-5508-9c7d-800c7b3cd381","slug":"drug-interactions","fullItemName":"Drug interactions","depth":3,"htmlHeader":"<!-- begin field be852965-5635-44d4-bbd1-aadb00c0d5db --><h3>What are the possible drug interactions of metronidazole?</h3><!-- end field be852965-5635-44d4-bbd1-aadb00c0d5db -->","summary":"","htmlStringContent":"<!-- begin item 7ba062fe-4bba-4b26-a3f6-aadb00c0d5b7 --><!-- begin field 242a4643-7fb8-4385-9a52-aadb00c0d5db --><ul><li><strong>Alcohol — </strong>some people taking metronidazole experience a disulfiram-like reaction with alcohol.<ul><li>Warn the person that they <em>might </em>experience this reaction if they drink alcohol whilst on metronidazole and for at least 48 hours afterwards. </li></ul></li><li><strong>Busulfan </strong>— plasma levels of busulfan may be increased leading to toxicity. Avoid high doses of busulfan. If conventional doses of busulfan are given, monitor blood count weekly.</li><li><strong>Ciclosporin —</strong> levels of ciclosporin may be increased. If co-administration of metronidazole and ciclosporin is necessary, serum ciclosporin levels and serum creatinine should be closely monitored.</li><li><strong>5-fluorouracil</strong> — metronidazole reduces the clearance of 5-fluorouracil, increasing the risk of toxicity.</li><li><strong>Lithium —</strong> seek specialist advice regarding the use of metronidazole with lithium, as metronidazole increases the risk of lithium toxicity. Lithium dose reduction may be required due to the risk of renal damage with concurrent use. Plasma concentrations of lithium, creatinine, and electrolytes should be monitored if metronidazole and lithium are used simultaneously.</li><li><strong>Oral hormonal contraception</strong> — additional contraceptive precautions are not required during or after courses of metronidazole.<ul><li>However, women should be advised about the importance of correct contraceptive practice if they experience vomiting or diarrhoea. For further information, see the sections on vomiting or diarrhoea in the CKS topics on <a class=\"topic-reference external-reference\" href=\"/topics/contraception-combined-hormonal-methods/\">Contraception - combined hormonal methods</a> and <a class=\"topic-reference external-reference\" href=\"/topics/contraception-progestogen-only-methods/\">Contraception - progestogen-only methods</a>.  </li></ul></li><li><strong>Phenobarbital —</strong> the metabolism of metronidazole is increased significantly. The dose of metronidazole may need to be increased.</li><li><strong>Warfarin</strong> <strong>—</strong> the anticoagulant effects of warfarin may be increased by metronidazole. <ul><li>Monitor the international normalized ratio (INR) and adjust the warfarin dose accordingly. </li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/cellulitis-acute/references/\">Preston, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/cellulitis-acute/references/\">ABPI, 2017c</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/cellulitis-acute/references/\">FSRH, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/cellulitis-acute/references/\">Joint Formulary Committee, 2019</a>]</p><!-- end field 242a4643-7fb8-4385-9a52-aadb00c0d5db --><!-- end item 7ba062fe-4bba-4b26-a3f6-aadb00c0d5b7 -->","subChapters":[]},{"id":"ebbdfbb6-009d-538f-a4d8-deecedccf965","slug":"pregnancy-breastfeeding","fullItemName":"Pregnancy and breastfeeding","depth":3,"htmlHeader":"<!-- begin field 99a1aec0-a6ee-44ee-9440-aadb00c0edd5 --><h3>Can metronidazole be used during pregnancy and breastfeeding?</h3><!-- end field 99a1aec0-a6ee-44ee-9440-aadb00c0edd5 -->","summary":"","htmlStringContent":"<!-- begin item a7dcc710-203b-4b4a-98cb-aadb00c0edaa --><!-- begin field 345c9230-67e2-415c-b257-aadb00c0edd5 --><h4>Pregnancy</h4><ul><li>Metronidazole is not known to be harmful in pregnancy, however the manufacturer advises that it should only be used if the benefit outweighs risks and that a single high dose regimen should be avoided.</li></ul><h4>Breastfeeding</h4><ul><li>Significant amounts of metronidazole are excreted in breastmilk, however it is compatible with breastfeeding, as it is of low toxicity and quantities are far less than those used therapeutically in infants.</li><li>The manufacturer advises against the use of high-dose regimens.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/cellulitis-acute/references/\">ABPI, 2017c</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/cellulitis-acute/references/\">Joint Formulary Committee, 2019</a>]</p><!-- end field 345c9230-67e2-415c-b257-aadb00c0edd5 --><!-- end item a7dcc710-203b-4b4a-98cb-aadb00c0edaa -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}